Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Wuerzburg University Hospital
- Target Recruit Count
- 576
- Registration Number
- NCT03948035
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany
🇩🇪Vivantes Klinikum Spandau, Berlin, Germany
🇩🇪Universitätsklinikum Münster, Münster, North Rhine-Westphalia, Germany
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 18
- Registration Number
- NCT03909412
- Locations
- 🇺🇸
Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 16
- Registration Number
- NCT03891355
- Locations
- 🇮🇹
AOU Senese - U.O.C. Ematologia, Siena, Italy
🇮🇹A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy
🇮🇹Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 454
- Registration Number
- NCT03859427
- Locations
- 🇺🇸
Oncology Consultants PA, Houston, Texas, United States
🇳🇱Gelre Ziekenhuizen, Apeldoorn, Netherlands
🇳🇱Spaarne Gasthuis, Hoofddorp, Netherlands
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Landspitali University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03815279
- Locations
- 🇮🇸
Landspitali University Hospital, Reykjavík, Iceland
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
- Conditions
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Duke University
- Registration Number
- NCT03805178
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT03798678
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 36
- Registration Number
- NCT03795597
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 12
- Registration Number
- NCT03773107
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Emory University
- Target Recruit Count
- 29
- Registration Number
- NCT03756896
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.